Sotigalimab
- Generic Name
- Sotigalimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2305607-45-6
- Unique Ingredient Identifier
- JEA93WJ5DG
- Background
Sotigalimab is under investigation in clinical trial NCT03123783 (CD40 Agonistic Antibody APX005M in Combination With Nivolumab).
- Associated Conditions
- -
- Associated Therapies
- -
Sotigalimab May Be a Safe and Feasible Addition to the Rectal Cancer Chemoradiotherapy
The INNATE trial (NCT04130854) found sotigalimab added to chemoradiotherapy safe and feasible for rectal cancer, with 22.2% pCR in sotigalimab arm vs 14.3% in control. 30 patients were randomly assigned, 93% completed therapy, and 80% had surgery. Grade 3/4 AEs were 26% in sotigalimab arm vs 45% in control, with no grade 5 toxicities in sotigalimab arm.
Related Clinical Trials:
MD Anderson Research Highlights Special Edition: ESMO 2024
MD Anderson researchers present at 2024 ESMO Congress on various cancer treatments: pembrolizumab for MSI-H/dMMR cancers, next-gen CDK4/6 inhibitors for HR+ HER2- breast cancer, cytokine levels predicting dyspnea response, CD40 agonist + pembrolizumab for melanoma, and COVID mRNA vaccines enhancing immunotherapy responses.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath